Tutzing, Germany
Tutzing, Germany

Time filter

Source Type

Patent
baseclick | Date: 2015-03-20

The present invention relates to methods for detecting an analyte in a sample utilizing self-assembly of nucleic acids to yield predetermined nanostructures. Further aspects of the invention relate to stabilizing nucleic acid nanostructures and to the use thereof in methods for detecting an analyte. Also provided are kits and devices for use in the described methods.


Patent
baseclick | Date: 2017-03-08

The present invention relates to methods for detecting an analyte in a sample utilizing self-assembly of nucleic acids to yield predetermined nanostructures. Further aspects of the invention relate to stabilizing nucleic acid nanostructures and to the use thereof in methods for detecting an analyte. Also provided are kits and devices for use in the described methods.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.56M | Year: 2015

Gene therapy is expected to play a key role in next-generation medicine by correcting the underlying genetic causes of disease, thereby facilitating personalised medicine. Current gene therapy methods possess undesirable side effects, including insertional mutagenesis, toxicity, low efficiency and off-target cutting. Questions also remain regarding the optimal methods for delivering nucleases into cells and tissues. These limitations will be addressed through the original and innovative approach of the ClickGene network. ClickGenes research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, i.) site-selective genetic engineering, ii.) liposomal nanoparticle drug delivery, and iii.) optogenetic diagnostic probes for epigenetic base detection. Most of our academic partners are key members of COST Action CM1201: Biomimetic Radical Chemistry and all have outstanding international reputations as scientific leaders in their field. This COST Action will play a vital role in both networking and training elements of ClickGene, and in combination with transferable skills training, intersectorial and cross-disciplinary secondment, and industry targeted workshops, the education of biomaterials chemists with expertise in click-chemistry and cutting edge application areas of gene therapy, nanotechnology and biological diagnostics will be achieved. The training provided will match the skills required by next-generation research leaders in biopharmaceutical, nanotechnology, biodiagnostic and other industries. Allied to academic strength in this network, ClickGene features highlycompetitive industry partners with expertise in commercialisation of nucleic acid click-chemistry (baseclick, ATDBio) and liposomal and lipidome technology (LipiNutraGen). Thus, synergy between both commercial and academic partners will enable ESRs to develop gene-targeted technology within a highly productive, engaging, and exciting training network.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 4.07M | Year: 2013

DNA Nanotechnology is an emerging interdisciplinary area that will underpin the development of future nanoscience-based technologies for areas such as medicine, diagnostic tools, optics and electronics. DNA nanotechnology is based on the unique self-assembly properties of DNA which allow the rational design and synthesis of complex nanoscale structures with predictable form and function. Many other materials can be integrated in such DNA structures to create highly functional nanodevices. The Marie Curie ITN EScoDNA will establish a sustainable European School of DNA Nanotechnology. By providing high quality training to young scientists, EScoDNA will improve their career prospects in both public and private sectors; it will also strengthen the competitive position of European research and industry in this promising strategic field. A network of leading European researchers, two SMEs and a major commercial research institute will work together to foster the development of a new generation of scientists with the skills required to meet future challenges in DNA nanotechnology, from fundamental science to novel applications. The training program will involve collaborative research projects, including international secondments and exchange of data through a web-based Lab-Wiki Journal, and through summer schools and workshops. The industrial partners will be integrated in the training programme, and the two SMEs will coordinate training related to the commercial exploitation of new technologies, management and entrepreneurial skills. They will also take a lead in managing the protection and commercialization of new technologies arising from research with the ITN. The programme is designed to create a pool of highly qualified researchers prepared for a wide range of careers in bionanotechnology and nanofabrication and, especially, capable of contributing to the development of a strong European centre for the scientific and commercial development of DNA nanotechnology.


The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.


The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.


Patent
baseclick | Date: 2013-07-10

The present invention refers to a conjugate comprising at least one polyunsaturated fatty acid residue, particularly an arachidonic acid residue, more particularly an anandamide (arachidonoyl ethanol amide) residue and covalently bound thereto at least one nucleosidic component selected from nucleic acids, nucleosides and nucleotides. This conjugate is suitable for the transfection of cells such as mammalian cells including human cells with high efficacy. Thus, a new delivery vehicle for therapeutic molecules including antisense molecules, siRNA molecules, miRNA molecules, antagomirs or precursors of such molecules, as well as the therapeutic nucleosides or nucleotides, is provided.


The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.


The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.


Patent
baseclick | Date: 2015-11-04

The present invention relates to methods for detecting an analyte in a sample utilizing self-assembly of nucleic acids to yield predetermined nanostructures. Further aspects of the invention relate to stabilizing nucleic acid nanostructures and to the use thereof in methods for detecting an analyte. Also provided are kits and devices for use in the described methods.

Loading baseclick collaborators
Loading baseclick collaborators